Globe Life Q4 2025 Earnings Call Transcript

AlphaStreet
Provided by AlphaStreet
February 6, 2025
Skip to Questions & Answers
Operator

Welcome to the Globe Life 4th-Quarter 2024 Earnings Release Conference Call. My name is Alan, and I'll be your coordinator for today's event. Please note this call is being recorded and for the duration, your lines will be on listen-only. However, you will have the opportunity to ask questions at the end. This can be done by pressing star one on your telephone keypad. If you require assistant at any time, please press star zero and you'll be connected to an operator. I will now hand you over to your host, Steven, Senior Director of Investor Relations to begin today's conference. Thank you.

Stephen Mota
Senior Director, Investor Relations at Globe Life

Thank you. Good morning, everyone. Joining the call today are Frank and Matt Darden, our Co-Chief Executive Officers; Tom, our Chief Financial Officer; Mike Majors, our Chief Strategy Officer; and Brian Mitchell, our General Counsel. Some of our comments or answers to your questions may contain forward-looking statements that provided for general guidance purposes only. Accordingly, please refer to our earnings release, 2023 10-K and a subsequent Form 10-Q on file with the SEC. Some of our comments may also contain non-GAAP measures. Please see our earnings release and website for a discussion of these terms and reconciliations to GAAP measures. I will now turn the call over to Frank.

Frank Svoboda
Co-Chief Executive Officer at Globe Life

Thank you, Stephen, and good morning, everyone. In the 4th-quarter, net income was $255 million or $3.01 per share compared to $275 million or $2.88 per share a year-ago. Net operating income for the quarter was $266 million or $3.14 per share, an increase of 12% from a year-ago. On a GAAP reported basis, return-on-equity through December 31 is 21.7% and book-value per share is $62.50. Excluding accumulated other comprehensive income or AOCI, return-on-equity is 15.1% and book-value per share as of December 31 is $86.40, up 13% from a year-ago.

In our life insurance operations, premium revenue for the 4th-quarter increased 4% from the year-ago quarter to $823 million. Life underwriting margin was $336 million, up 10% from a year-ago, primarily driven by premium growth and lower overall policy obligations. In 2025, we expect life premium revenue to grow at the midpoint of our guidance in the range of 4.5% to 5% compared to 4% growth for 2024. As a percentage of premium, we anticipate life underwriting margin to be between 40% and 42%.

In health insurance, premium revenue grew 7% to $358 million, while health underwriting margin declined 6% to $91 million due primarily to higher claim costs at United American resulting from higher utilization. In 2025, we expect health premium revenue to grow in the range of 7.5% to 8.5% compared to 6.5% growth for 2024. We also expect health underwriting margin as a percent of premium to be between 25% and 27%.

We are pleased with the overall premium growth we saw in 2024 as the 4.7% growth in total premium income was well-above the 3.4% growth rate in 2023. This is especially encouraging as we come out-of-the high inflationary period that has put a stress on the US consumer, especially those in the demographic we serve and demonstrates the resiliency of our business. Due to the continued efforts of our sales and conservation teams, we anticipate this growth rate to accelerate and be even higher in 2025. Administrative expenses were $91 million for the quarter.

The increase is primarily due to higher information technology costs related to maintaining IT software and services, employee costs and legal expenses. While our expenses in the 4th-quarter were higher than prior quarters, they were largely in-line with our expectations. In 2025, we expect administrative expenses to be approximately 7.4% of premium. I will now turn the call over to Matt for his comments on the 4th-quarter marketing operations.

Matt Darden
Co-Chief Executive Officer at Globe Life

Thank you, Frank. At American Income Life, Life premiums were up 7% over the year-ago quarter to $433 million and Life underwriting margin was up 9% to $199 million. In the 4th-quarter of 2024, net life sales were $93 million, and this is up 22% from a year-ago and primarily due to increased productivity and agent count growth. The average producing agent count for the 4th-quarter was 11,926, up 7% from a year-ago.

This growth is due to the continued focus on recruiting and improved new agent retention. And I continue to be very pleased by the momentum at American Income. At Liberty National, our life premiums were up 5% over the year-ago quarter to $94 million and the life underwriting margin was up 8% to $34 million. Net life sales increased 1% to $26 million, while net health sales were $9 million, down 5% from the year-ago quarter.

The average producing agent count for the 4th-quarter was 3,743, up 11% from a year-ago. And I'm excited to see the continued agent count growth at Liberty National, which is primarily driven by our recruiting activity and agency middle-management growth. And I am confident that this growth in agent count and agency middle-management will drive strong sales growth in 2025. At Family Heritage, the health premiums increased 8% over the year-ago quarter to $11 million and health underwriting margin increased 12% to $40 million. Net health sales were up 6% to $27 million due primarily to an increase in agent count.

The average producing agent count for the 4th-quarter was 1,512, and this is up 11% from a year-ago. And I continue to be pleased to see the agent count growth, which is driven by this agency's efforts in recent quarters to emphasize recruiting and middle-management development. At our direct-to-consumer division at GlobeLife, life premiums were down 1% over the year-ago quarter to $245 million, while life underwriting margin increased 20% to $71 million.

Net life sales were $23 million, down 11% from the year-ago quarter. Now as we've mentioned previously, the continued decline in sales is primarily due to lower customer inquiries as we have reduced our marketing spend on certain campaigns that did not meet our profit objectives as a result of higher distribution cost. Our focus in this area is having a positive impact on our overall margin as we will continue to focus on maximizing the underwriting margin dollars on new sales by managing the rising advertising and distribution costs associated with acquiring new business.

The value of our direct-to-consumer business is not only those sales directly attributable to this channel, but the significant support that is provided to our agency business through brand impressions and sales leads. As we mentioned last quarter, we expect this division to generate over 750,000 leads during 2025, which will be provided to our three exclusive agencies.

At United American General Agency, here the Health premiums increased 9% over the year-ago quarter to $151 million, driven by strong prior year sales growth of 23%. Health underwriting margin was $5 million, down approximately $9 million from the year-ago quarter due to higher claim costs resulting primarily from higher utilization. For the full-year 2025 , we anticipate mid-single-digit growth in our underwriting margin due to strong sales and premium pricing actions. Net health sales were $30 million, up 7% over the year-ago quarter. Now I'd like to discuss our projections. And based on the recent trends and our experience with our business, we expect the average producing agent count trends for the full-year 2025 to be as follows. At American Income, some single -- mid-single-digit growth at Liberty National, low double-digit growth and at Family Heritage also low double-digit growth. We'd also like to reaffirm our Life and health sales guidance we gave on our last earnings call. And as a reminder, this was not where net life sales were 2,000. Net life sales for 2025 are expected to be as follows: American Income, high-single-digit growth; Liberty National, low double-digit growth and our direct-to-consumer division, low-to-mid single-digit growth. Now for health sales, we expect Liberty National, Family Heritage and United American General Agency to all have low double-digit growth. Now before I turn the call-back over to Frank for investment operations, I'd like to make a few brief comments regarding the inquiries made by the SEC and the DOJ that we have previously discussed. While these inquiries are still open, there have been no material developments and neither agency has asserted any claims or made any allegations against GlobeLife or AIL and we're not aware of any actions being contemplated by the SEC or SEC or the DOJ. And with respect to the EEOC matter, as of now, there have been no material developments to share outside of what was disclosed within our 10-Q as filed on November 6, 2024. And to the extent there's further information to share on any of these items, we will update you accordingly. I'll turn the call-back now to Frank.

Frank Svoboda
Co-Chief Executive Officer at Globe Life

Thanks, Matt. We will now turn to the investment operations. Excess investment income, which we define as net investment income once only required interest was $38 million, up $3 million from the year-ago quarter. Net investment income was $282 million, up 4% or $11 million from the year-ago quarter. The increase is largely due to the 3% growth in average invested assets over that period and to a lesser degree, higher interest rates.

Required interest is up 3.5% over the year-ago quarter, in-line with the growth in average policy liabilities. For the full-year 2025, we expect net investment income to be fairly flat and require interest to grow around 2.5%. The growth in both our average invested assets and our average policy liabilities is lower than historical levels due primarily to the reinsurance of approximately $460 million of our in-force annuity reserves that we noted on our last call. This agreement was effective November 1. In addition, the impact of higher subsidiary dividends to the parent in 2025 will also contribute to lower average invested asset growth. As such, we anticipate excess investment income to be flat-to-down 15%.

Now regarding our investment yield. In the 4th-quarter, we invested $378 million in investment-grade fixed maturities, primarily in the industrial and financial sectors. These investments were at an average yield of 5.83% at an average rating of A-minus and an average life of 35 years. We also invested approximately $52 million in commercial mortgage loans and limited partnerships with debt-light characteristics at an average expected cash return of approximately 8.5%.

None of our direct investments in commercial mortgage loans involve office properties. These non-fixed maturity investments are expected to produce additional cash yield over our fixed maturity investments, while still being in-line with our conservative investment philosophy. For the entire fixed maturity portfolio, the 4th-quarter yield was 5.27%, up 4 basis-points from the 4th-quarter of 2023 and up 2 basis-points from the 3rd-quarter. As of December 31, the portfolio yield was 5.25%. Including the cash yield from our commercial mortgage loans and limited partnerships, the 4th-quarter earned yield was 5.41%.

Now regarding the investment portfolio. Invested assets are $21.2 billion, including $18.8 billion of fixed maturities at amortized cost. Of the fixed maturities, $18.3 billion are investment-grade with an average rating of A-minus. Overall, the total fixed maturity portfolio is rated A-minus, same as a year-ago. Our fixed maturity investment portfolio has a net unrealized loss position of approximately $1.7 billion due to the current market rates being higher than the book yield on our holdings.

As we have historically noted, we are not concerned by the unrealized loss position as-is mostly interest-rate driven and currently relates entirely to bonds with maturities that extend beyond 10 years. We have the intent and more importantly, the ability to hold our investments to maturity. Bonds rated BBB comprise 46% of the fixed maturity portfolio compared to 48% from the year-ago quarter. This percentage is at its lowest level since 2007. As we have discussed on prior calls, we believe the BBB securities we acquired generally provide the best risk-adjusted capital-adjusted returns due in-part to our ability to hold securities to maturity regardless of fluctuations in interest rates or equity markets.

While the percent of our invested assets comprised of BBB bonds might be a little higher than some of our peers. Remember that we have little or no exposure to other higher-risk assets such as derivatives, equities, residential mortgages, CLOs and other asset-backed securities. Below investment-grade bonds remain at historical lows at $525 million compared to $530 million a year-ago. The percentage of below investment-grade bonds to total fixed maturities is just 2.8%. At the midpoint of our guidance, for the full-year 2025, we expect to invest approximately $900 million to $1.1 billion in fixed maturities at an average yield of 5.5% to 5.7% and approximately $300 million to $500 million in commercial mortgage loans and limited partnership investments with debt-like characteristics at an average expected cash return of 7% to 9%. Now, I will turn the call over to Tom for his comments on capital and liquidity.

Tom Kalmbach
Chief Financial Officer at Globe Life

Thanks, Rick. Let me spend a few minutes discussing our share repurchase program, available liquidity and capital position. The parent began the year with liquid assets of approximately $48 million and ended the year with approximately $90 million. In the 4th-quarter, the company repurchased approximately 338,000 shares of GlobeLife common stock for a total cost of approximately $36 million at an average share price of $105.37.

This was slightly higher than we had anticipated in the quarter. For the full-year, we purchased 10 million shares for a total cost of $946 million at an average share price of $93.76, including shareholder dividend payments of $85 million, the company returned slightly more than $1 billion to shareholders during 2024. In addition to the liquid assets held by the parent, the parent company will generate excess cash flows during 2025. The parents company's excess cash-flow as we define it results primarily from dividends received by the parent from its subsidiaries less interest paid on debt.

Although our statutory results are not final, we anticipate the parent company's excess cash-flow for the full-year 2025 will be approximately $785 million to $835 million. Excess cash flows are anticipated to be higher in '25 than in '24, primarily as a result -- as resulting from higher statutory earnings in '24 than in 2023, as well as the impact of previously discussed reinsurance transactions completed in 2024. Statutory income in 2024 is anticipated to be higher than statutory income in 2023, primarily from favorable investment results, statutory reserve changes, improved mortality results and lower realized losses.

At the midpoint of our guidance, the anticipated excess cash flows are expected to be used to distribute approximately $85 million to shareholders in the form of dividend payments and reduce commercial paper to more historical levels with the remainder expected to be used for share repurchases in the range of $600 million to $650 million absent an alternative use with a higher-return to our shareholders. We anticipate liquid assets at the parent of around $60 million at the end-of-the year. We still believe share Share repurchases provide the best return or yield to our shareholders. Thus, we anticipate share repurchases will continue to be the primary use of the parent's excess cash flows after the payment of shareholder dividends. With regards to capital levels at our insurance subsidiaries, our goal is to maintain our capital levels necessary to support our current ratings. GlobeLife targets a consolidated company action level RBC in the range of 300% to 320%. Since our statutory financial statements are not yet final, our consolidated RBC ratio is not yet known. However, we anticipate the final 2024 RBC ratio will be within our targeted range. Now with regards to policy obligations for the current quarter, as we discussed on prior calls, Life and health assumption changes were made in the 3rd-quarter. No assumption changes were made in the 4th-quarter. The supplemental financial information available on our website provides an exhibit that details the quarterly remeasurement gain or loss by distribution channel. For the 4th-quarter, Life obligations to continue to be favorable when compared to our assumptions of mortality and persistency, resulting in lower policy obligations and a $19 million remeasurement gain related to experienced fluctuations. For the full-year, encompassing both assumption changes and experience related fluctuations, the remeasurement gain from the Life segment resulted in a $107 million of lower life policy obligations and for the health segment, $3 million of higher health policy obligations. In recent quarters, mortality trends in the Life segment has been favorable relative to our long-term assumptions. If mortality continues to develop favorably over the next couple of quarters, life obligations will be favorable relative to our long-term assumptions, resulting in-life remeasurement gains. Conversely, if mortality experiences higher than our long-term assumptions, we will experience life remeasurement losses. Recent mortality lapse experience will inform future updates to long-term assumptions, which we intend to make in the 3rd-quarter of 2025. For the Health segment, we anticipate health -- health obligations for our Medicare supplement and group retiree health products will continue to be elevated given recent claim trends outpacing premium rate increases. Finally, with respect to our earnings guidance for 2025, for the full-year 2025, we estimate net operating earnings per diluted share will be in the range of $13.45 to $14.05, representing 11% growth at the midpoint of our range. The $13.75 midpoint is higher than our previous guidance due to the favorable mortality experience we've seen in recent quarters and the anticipation that these favorable mortality trends will continue into 2025, resulting in improved life underwriting margins. Those are my comments. I will now turn the call-back to Matt.

Matt Darden
Co-Chief Executive Officer at Globe Life

Thank you, Tom. Those are our comments, and we will now open the call up for questions

Skip to Participants
Operator

Thank you. If you'd like to ask a question or make a contribution on today's call please press star one on your telephone keyped. To withdraw your question please press star to. You'll be advised when to ask your question. We will take our first question from Jimmy Poolar, JPMorgan. Your line is open. Please go-ahead.

Jimmy Bhullar
Analyst at JPMorgan Chase & Co.

Hey, good morning. So first, just a question on your results. I thought overall most of the business metrics were good, but one of the negatives was just a little bit of an increase in first year lapses in the direct channel and also in Liberty. And so hoping if you could discuss what's really causing that and do you expect that trend to continue to get worse as you get through 2026 or '25?

Matt Darden
Co-Chief Executive Officer at Globe Life

Can we take that?

Frank Svoboda
Co-Chief Executive Officer at Globe Life

Yeah.

Matt Darden
Co-Chief Executive Officer at Globe Life

And Jimmy, I think a couple of things. I think we are pleased overall with that lapse experience has stabilized and in AIL actually lapse rates went down a little bit. Overall for Liberty, they went down a little bit from sequential quarters. So I think there's some good news there that the higher lapse rates that we had seen and stabilized a bit. On DTC, we are seeing a little bit higher lapse rates than we have historically and some of that is mix of business that quite a bit of our new business is coming from the Internet channel versus our more of our mail and insert media channels. So those digital channels do experience a little bit higher lapse rates and I think that's at least part of the story there.

Frank Svoboda
Co-Chief Executive Officer at Globe Life

Yeah. One thing, Jimmy, I would just add to that. Really, if you go back and look at American income and especially kind of their average first year lapse rates, especially pre-pandemic, right in-line with where that always fluctuates, of course, on a quarterly basis. And really it's not really that measurably higher than even the long-term average since 10, 15 years?

Jimmy Bhullar
Analyst at JPMorgan Chase & Co.

Okay. And then on the regulatory investigation, especially on the DOL and the SEC, from the outside-in, how does one get finality to this? Because typically those agencies don't tend to put out releases when they're done investigating something unless there's a fine or something else. But what's your view on how somebody would get -- obviously, the passage of time without any new news is a positive. But other than that, how does one get finality -- how do -- how should we see some finality or a resolution to this from the outside?

Matt Darden
Co-Chief Executive Officer at Globe Life

Yeah. Thanks, Jimmy. Our intent is to be able to disclare the conclusion of those inquiries when they happen. Of course, we're working through those processes as we speak. But our -- you're right, generally, the agencies themselves don't issue something, but our intent would be able to communicate when those inquiries have been concluded at the time that happens.

Jimmy Bhullar
Analyst at JPMorgan Chase & Co.

And then if I could just ask one more. On the health business, there was some optimism last year that with the reimbursement rate changes on plans, maybe there would be more volumes flowing towards up. It seems like now the trend could actually end-up reversing and up, the market might shrink a little bit, but what are your thoughts on that given the change in the administration?

Matt Darden
Co-Chief Executive Officer at Globe Life

Yeah. That one is an interesting one that we want to watch. There's been some in the new administration that have voiced some optimism around MA plans. But I do believe also there is a segment of consumers and frankly, providers that may be disenfranchised with the structure of Medicare Advantage plans. And I think that would still could be a benefit to the Medicare supplement market because people still do like choice. And again, there are certain providers that have not been happy with reimbursements on the MA and MA side. So it's one of those that we're watching and seeing. I don't think it's too early to conclude one-way or another how that market is going to shake-out with the new administration.

Jimmy Bhullar
Analyst at JPMorgan Chase & Co.

Thank you

Operator

Thank you. We will take our next question from Jake, BMO Capital Markets. Your line is open. Please go-ahead.

Jack Matten
Analyst at BMO Capital Markets

Hi, good morning. Just a first question, your excess cash-flow guidance and the higher guidance you gave for 2025. I guess, are you able to quantify the different elements of that across the reinsurance accounting changes and maybe the favorable underlying results that you mentioned? Just trying to get at what how much of the increase was more maybe one-time in nature and how much you would expect to kind of persist into your outer year run-rate?

Tom Kalmbach
Chief Financial Officer at Globe Life

Yeah. So thanks for the question. Yeah, the -- one of the increases is the reinsurance transactions that we did last year and the -- as I indicated on the call that those were worth about $100 million. So we actually did file for an extraordinary dividend and got approval at the end-of-the year. So that's providing some additional excess liquidity to the parent in 2025 and that's reflected in those numbers as well, which incorporates the impact of those reinsurance numbers.

The other kind of run-rate is statutory earnings are a bit higher because of some valuation manual changes and there's a little bit of a catch-up there. And in the full-year benefit of that was probably closer to $150 million versus the $120 million that I had estimated at last quarter. And that probably cuts in half as we kind of look at it as we go -- as we go further out into '20, the benefit that we might see from that from a normal run-rate in 2025 and on?

Jack Matten
Analyst at BMO Capital Markets

And a question on the life margin and the higher guidance there. I guess is that some effect related to maybe near-term experience that would flow-through kind of the remeasurement gains? And I guess I know you had your like assumption last quarter. If anything in particular that's driving the improved outlook now versus what you had coming out of that reveal.

Frank Svoboda
Co-Chief Executive Officer at Globe Life

Yeah. We really saw -- I think what we Saw in the 4th-quarter was just some really good mortality experience and especially development on the claims that were incurred in -- that incurred in Q3 and Q2. So as you know, even though you kind of were looking at some of the favorable experience that we were seeing early in the year and that at least was an input into how we thought about the assumptions. Really in the 4th-quarter, we just -- we saw some very good experience taking place. And so we continue to have a pretty sizable remeasurement gain in Q4 just since that was so much better than that long-term assumption that we had in-place.

Jack Matten
Analyst at BMO Capital Markets

And thank you

Operator

We will take our next question from Elyse Greenspan, Wells Fargo. Your line is open. Please go-ahead.

Elyse Greenspan
Analyst at Wells Fargo & Company

Hi, thanks. Good morning. My first question is on buyback. Should we just think about on that kind of being evenly spread on the guide throughout the four quarters of the year? And then I know, right, you guys prior to some of the DOJ investigations, right, there was some deal you guys were considering. Do you consider M&A, I guess, kind of returning to the equation in 2025 embedded within your capital outlook?

Tom Kalmbach
Chief Financial Officer at Globe Life

Yeah. I'll start with that is we did begin share repurchases again at the beginning of the year and stopped that as we entered into a blackout period. But we would -- our plan is to continue kind of our historical practices around share repurchases, which is ratable throughout the year and so it might not be evenly ratable, but generally consistent throughout the year.

Frank Svoboda
Co-Chief Executive Officer at Globe Life

And then -- and one of the reasons we do that is that it does allow us to kind of really manage those cash flows. So if we do see an M&A opportunity, you we think is really beneficial for the shareholders, then we can pivot and use some of those cash flows for that. I mean, we will continue to be open to M&A opportunities and continue as we've talked about on prior calls, really looking for something that helps us to expand our offerings, if you will, in the -- to serve middle-income policyholders with basic protection products and that comes with some type of distribution. So we will continue to be looking for those opportunities and open to those opportunities if they arise.

Elyse Greenspan
Analyst at Wells Fargo & Company

Thanks. And then my second question, health utilization did trend up in the second-half of last year. Can you just provide some kind of color on your thoughts for 2025 there as well?

Tom Kalmbach
Chief Financial Officer at Globe Life

Yeah. I mean, definitely health utilization was high during the course of 2024 and actually we saw it get a little bit higher in 2025. It's kind of one of the reasons why we've adjusted our range for health underwriting margin overall. It's just that we continue to believe that utilization will continue to run a little bit high and outpace the rate increases that we've actually filed and gotten approved for premium increases in 2025. So over-time, I think we'll catch-up with that. But I think in 2025, we do expect to see higher utilization.

Elyse Greenspan
Analyst at Wells Fargo & Company

Thank you.

Operator

We will take our next question from Wilma Raymond James, your line is open. Please go-ahead.

Wilma Burdis
Analyst at Raymond James

Hey, good morning. So if I took out the reinsurance and the valuation manual updates, I'm estimating organic excess cash-flow of around -- I think it was around $550 million to $600 million. Is that a good base? And then the $75 million or I guess, half of $150 million that you expect to continue in '26 over what timeframe will that persist? Thank you.

Tom Kalmbach
Chief Financial Officer at Globe Life

Yeah. Thanks, Wilma. I think your base is good. I don't -- we haven't really finalized 2024 statutory earnings. And so next quarter, I could give you a better update on kind of where we think that run-rate is. I think one of the things we want to factor-in is that investment income is expected to be fairly flat. So I think that's going to limit some of that upside. So we're going to -- we can give you an update next quarter on that as well once we finalize statutory earnings. But I think you're in the ballpark anyway.

The -- and then on the valuation manual changes, I think we saw in '24, that was really kind of an impact to the in-force business. And so as the in-force business goes -- as that subsides from the existing in-force business, some of it will be made-up by new business that comes on. So I think although I don't have a crystal ball there, I think that's a -- that $70 million that is the midpoint or half of that is -- will decline a little bit over-time, but I think a lot of that is sustainable additional statutory earnings,

Wilma Burdis
Analyst at Raymond James

Thank you. And then could you talk a little bit about what the recruiting and sales environment is like right now from a macro perspective? Middle-income consumers seem to be in a modestly better financial condition. Does that have any impact on-sales and recruitment? And then can you talk a little bit about what you're seeing in the point in the market? Thanks.

Matt Darden
Co-Chief Executive Officer at Globe Life

Yeah. Thanks, Wilma. I think we're still seeing some strong growth in our recruiting efforts and hiring efforts. And so we anticipate that to continue forward into 2025. And so that's reflective in the growth numbers that we're anticipating on our agent count side. And then, of course, that translates into our sales growth. One of the things we just wanted to acknowledge for -- as an example, for American income, we're coming off of four -- prior to Q4, we're coming off of four quarters of double-digit growth and in some cases, very-high up to 20% growth if I go back four quarters ago.

And so we're tempering that a little bit of just maintaining 15% and 20% agent count growth quarter-over-quarter is a little bit higher than our historical norms. But again, I still think we're going to have a good environment for 2025 if I look at just our momentum across all three agencies coming out-of-the end of '24. Then on the sales side, we continue to see growth there. We actually -- as we look at the new business that we're selling, we're having improvements in just the premium on a per policy basis. And so as we've discussed before, the macroeconomic environment, we seem to be pretty resilient from that is, I go back to when we were experiencing 8% and 9% inflation rates, we were still able to grow both on the recruiting agent count side as well as on the sales side. And so we continue to see our customer-base be very resilient.

And I think that just gets back to this marketplace, continues to have a significant amount of opportunity with a significant number of people that are underinsured or uninsured in this marketplace, and we have a good opportunity to continue to develop sales in that area. And as we've discussed before, the benefit, I think of our policies is the small -- their basic protection, they're easy-to-understand. They're designed for middle-income America and the premiums are small on a relative basis per month, depending on the channel, they're -- they're $30 to 60 a month-in premium.

And so it's not really price prohibitive to take-out those kind of policies for our customers. And I think that gets into the resiliency of our in-force base as we talk about. There are lapse rates that we discussed, they move around a little bit, but it's in a pretty Narrow-Band as different economic cycles kind of go

Operator

We will take our next question from John Brownish, Piper Sandler. Your line is open. Please go-ahead.

John Barnidge
Analyst at Piper Sandler Companies

Thank you for the opportunity. My first question is on agent trends, and I appreciate that you gave the guidance for agent growth for the year. But and I understand there's some seasonality in the 4th-quarter with the holidays, that occurs, but how have first year agents trended in January and essentially first-quarter so-far across those channels.

Matt Darden
Co-Chief Executive Officer at Globe Life

Yeah, John, you're right is -- it's not unusual around the holidays. So the latter half of Q4 and frankly , sometimes that bleeds over into the very first part of Q1. We do have a little bit of seasonality on the recruiting and agent retention side. And so our guides are really reflective of the entire year. And generally, we see a pickup in -- particularly in Q2 and within Q3 of strong agent count growth. And so really, as we've discussed before, we like -- we talk about it quarter-over-quarter, but we really like looking at it on a year-over-year basis. And what I'm very pleased about is that we have very-high correlation between producing agent count and our sales. So for example, if you look at a three-year CAGR for American Income. We have about 8% agent count growth and we have about an 8% sales growth over that time-frame and similar statistics if I walk-through Liberty and Family Heritage. So our long-term potential is really focused on around that 10% agent count growth and trying to achieve a similar number for our sales growth that really drives our expectation for our premium earnings that ultimately are in our results for the year. So I'd say, to answer your question, I don't -- the 4th-quarter activity is kind of what I would expect to be normal from a little bit of seasonality and I think we're starting off strong for this year-around what we would expect and how that builds over-time.

John Barnidge
Analyst at Piper Sandler Companies

And then on my follow-up question, I know you're doing some efforts to get a Bermuda platform up. Any update you can provide or any markers on the way station we should watch out for? Thank you.

Matt Darden
Co-Chief Executive Officer at Globe Life

Yeah. Yeah, thanks. The -- I think we're on-track with our analysis. We had communicated that we update you kind of midyear as far as what our plans are there and we're on-track to do that. So we feel pretty good with where we are.

Operator

We will take our next question from Wes Carmichael Autonomous Research. Your line is open. Please go-ahead.

Wes Carmichael
Analyst at Autonomous Research

Hey, thank you. Good morning. I had a broader question on the stock and capital management. But obviously, the stock came under some intense pressure last year and you as a management team took some pretty significant actions and bought back a lot of stock. And I understand your guidance for 2025, but as you sit here today, the stock is still trading at a pretty significant price earnings multiple discount relative to historical trends. So just curious how you're thinking about taking any other reinsurance, more significant action or are you feeling a little bit more business-as-usual now? Or are you waiting on maybe some of these investigations to conclude?

Frank Svoboda
Co-Chief Executive Officer at Globe Life

Yeah. Thanks, Wes. You know, as we really do look at it, we really do think that there's still some opportunities clearly in the valuations of our shares. I do think we will continue to look really hard at where are there pockets of opportunity for us to manage that capital, are there opportunities for us to release some additional capital over the course of the year. So we are continuing to look at some of those opportunities. And we still -- we do think that the stock is a good buy. So we will be taking a look at that.

Now I'd say that and I think as we mentioned earlier, from a timing perspective, largely want to be thinking about our share purchases coming over the course of the year and there may be a little bit of a front-end of loading on that just a little bit, but for the most part, it helps us to manage cash flows over the course of the year. But again, I think we'll continue to look at opportunities and try to be a little bit aggressive with respect to freeing up some additional cash or additional capital in order to take advantage of your current share price?

Wes Carmichael
Analyst at Autonomous Research

Got it. That's helpful. And I just had two kind of housekeeping follow-ups. I think in the -- in the release, there were some legal accruals about $12.5 million below-the-line. That's a little bit chunkier than its run. Can you just talk about the nature of what you're booking there? And my follow-up was just on commercial paper. Can you give us a sense on how much you're allocating excess cash flows this year for that.

Matt Darden
Co-Chief Executive Officer at Globe Life

Yeah. So as you know, GlobeLife and its subsidiaries are subject to litigation from time-to-time. And it's common in the insurance and that's in common in the insurance industry in general. We've seen an update, an uptick in litigation claims and expenses over the past several quarters as well as legal expenses stemming from claims made by recent short-sellers. The line-item for legal proceedings this quarter includes an estimate of costs associated with settlements of certain litigation claims not related to the DOJ, SEC or EEOC matters as well as certain other legal expenses that we incurred.

As we are sure you can appreciate, our policy is to refrain from commenting on pending or ongoing legal matters involving the company or any of its subsidiaries. So we're unable to provide any more detail at this time.

Frank Svoboda
Co-Chief Executive Officer at Globe Life

And then and then -- I think with respect to the commercial paper, right now, we're kind of -- we're looking at trying to bring that down into probably those more normal levels somewhere in the low 300s. I think we ended the year-around $415 million. So kind of pointing to around that $100 million or so of use of that to get it back. And really we'll kind of look at that over the course of the year and look at cash availability and cash-flow needs as well. But you know, we kind of manage that to help again manage our overall of liquidity risk and how we just think of having cash available for our operations. So we'd like to try to get that back into a little bit more of a normal string -- normal range if we are able to.

Wes Carmichael
Analyst at Autonomous Research

Thank you.

Operator

We will take our next question from Andrew, TD Securities. Your line is open. Please go-ahead.

Andrew Kligerman
Analyst at TD Securities

Hey, good morning. So my first question is around your shift in American income to virtual. Clearly, 2024 was really strong in terms of recruiting and sales. And now you said it would moderate a bit this year, but it's still very good, right? You said average agent counted AI would be mid-single digit and then you said life sales would be up at American Income high-single-digit and some of that I think you mentioned was a reflection of higher policy limits. But I'm kind of curious, like maybe moving out to '26 or even longer-term, you know, what kind of an impact is the virtual approach versus in-office having on your recruiting on your sales. I mean, is this something where we could see a big pickup in 2026 again? And how are you thinking about this longer-term? It sounds like something better is happening.

Matt Darden
Co-Chief Executive Officer at Globe Life

Yeah. Thanks, Andrew. We've started the virtual sales and virtual recruiting during the height of the pandemic and all that was associated with that. And we found such a benefit to it is that we've kept that model going-forward. And really, we're seeing a lot of good activity associated with that. On the agent recruiting side, what we see is that I think we're attracting additional individuals that may not have been interested in a sales opportunity that was face-to-face in a customer's home across the kitchen table, as they would say, is now those sales can be done from the comfort of their home or wherever they may be located.

And you can see what's happening with corporate America with a return back to the office and you see more-and-more companies announcing back to the office mandates and the like and that's providing additional tailwind to our opportunity as individuals are looking for flexibility and autonomy and the ability to do that. And so that has definitely benefited our recruiting efforts over the last many quarters. As I had mentioned, I go back to starting in early 2023, we've had 20%, 15%, 13%, et-cetera, agent count growth throughout the end of '23 through '24.

And I think know that will continue to be a benefit to us that virtual environment. And then the same thing happens on the sales side is that the ability for our agents to work leads throughout the area where they're licensed. So we've seen our agents have an uptick in-licensing in multiple states to be able to work leads Leads across state lines. And so it's just much more efficient from that perspective if I look at our agent activity as well as we were on the benefit of the consumer has changed. The consumer now is much more used to having virtual interactions. You have virtual interactions with your doctor from a telemed perspective and there's a variety of other interactions and so you have the consumer much more willing, I think now as compared to prior to 2020, being willing to have sales interactions through a virtual experience as well. So we don't really see that abating anytime soon. I think that's just kind of a new normal as we go-forward. And so we think that will continue to be a benefit. I'm very pleased with American income. If I look at as an example, their five-year CAGR from a agent count growth perspective, it's over 9% and that lines up very well with approximately 9% sales growth over that same timeframe. So they're very much in lockstep over a longer-term perspective. And so like we've talked about before, we get quarter-to-quarter fluctuations a little bit, but that long-term growth, we believe is definitely sustainable.

Andrew Kligerman
Analyst at TD Securities

Very helpful. And then just shifting over to the life underwriting margin, which came in at 41% and you're guiding in '25 to 40% to 42%. That's pretty nice just given in '23, it was about 38%. And as I kind of went through the supplement, it looks like a lot of the benefit this year came from direct-to-consumer. Was that -- is that the right observation? Have you kind of corrected for something in direct-to-consumer? And do you think the 41% is very sustained or 40% to 42% is sustainable beyond 2025.

Frank Svoboda
Co-Chief Executive Officer at Globe Life

Yeah, Andrew, I think you are right in the observation that we really are seeing some favorable developments on direct-to-consumer especially. It's been -- and that tends to be the segment or the distribution that's a little bit more of a -- insures a wider swath of the US population and does of course have -- tends to have higher mortality in general than each of the other distributions have. So as there's coming out-of-the COVID, we're seeing a lot of excess deaths and that's what we're seeing in the US population as a whole.

And the -- and so it's -- as we've been seeing here over the last couple of years, especially 2024, I mean our paid claims in 2024 have been basically flat, if not dropped a little bit from 2023, while at the same time, premium increased in 2024 by 4%. So we're really seeing that kind of a really favorable experience. And especially in the last couple of quarters here of this year, Q3 and Q4, we just saw really good experience and low levels of claims. And in certain causes of death, I'm actually seeing that at below some of those pre-pandemic levels.

And so we're -- we'll see how -- I think with respect to 2025, it really depends on will we continue to see that continuing level of favorable mortality persist or is it a fluctuation that we just happened to maybe be seeing here over the last few quarters. That's within the range kind of takes into account whether or not it -- we continue to see some of that favorable mortality or not. And we're of course hopeful that we will and then we'll be -- and go from there. And again, beyond 2025, you know, there's a lot of things to kind of work their way out here and we'll kind of see -- we've talked for the last couple of years of whether was there some pull-forward of deaths from COVID and would that result in some better mortality.

And of course, at the time, it was like, well, it's always possible, but it's really too early to tell. And again, maybe we are seeing a little bit of that, but again, we're kind of still waiting to see how that kind of pans out here over the next several quarters and then we'll get a better sense of whether we think that will persist or not.

Andrew Kligerman
Analyst at TD Securities

I mean, just a quick follow-up on that, just more specifically to direct-to-consumer, it sounds like you're gaining a little confidence because you guided to low-to mid-single-digit sales growth. Is that -- is that the right way to think about it?

Matt Darden
Co-Chief Executive Officer at Globe Life

Yeah, we're really looking at -- we think we've kind of bottomed-out, so to speak, a new level and been able to kind of maintain and grow a little bit from here. As we've talked about before, you know, that is one of our areas that is a little bit more price-sensitive. It's a passive sale that has a little bit more sensitivity to competition and economics, so to speak. So -- but we do think and that's why we guided to that what we did is we do think we're kind of bottoming out here and being able to have a new level to grow from.

Andrew Kligerman
Analyst at TD Securities

Thanks so much

Operator

We will take our next question from Sunit Kamar, Jefferies, your line is open. Please go-ahead.

Suneet Kamath
Analyst at Jefferies Financial Group

Great. Thank you. I know you hit on this earlier, but I just wanted to follow-up on potential reinsurance transactions. Should we assume that maybe things are on-hold a little bit until you get your Bermuda subsidiary sort of that whole strategy set-up or could you be contemplating doing something even before that happens?

Tom Kalmbach
Chief Financial Officer at Globe Life

I mean, I think we'll consider other opportunities, but I think really our focus is quite a bit on that Bermuda completing our analysis on the Bermuda subsidiary and making some final decisions there. But look, we'll be -- we're open to some other reinsurance opportunities if they make sense to us. So, but I think that's -- it's fair that our priority is on the Bermuda. Yeah.

Frank Svoboda
Co-Chief Executive Officer at Globe Life

One thing I would add is, I mean, there's always some transition and as Tom has talked about, Bermuda takes a little bit of time to get-in place and for there actually to get some measurable benefits from that type of transaction. So we're at least open to and thinking about is there something kind of in the interim that helps us to kind of -- we can do something that bridges the gap and gives us some benefits a little bit earlier.

Suneet Kamath
Analyst at Jefferies Financial Group

Yeah. Okay. That makes sense. So maybe Bermuda is more of a '26 kind of story than a '25 story? Yeah. I think it gives a little bit of benefit in '26. I think the real benefit comes in '27 and once we have two full years of financials for that we can get reciprocal jurisdiction, which is one of the requirements for doing that.

Frank Svoboda
Co-Chief Executive Officer at Globe Life

Yes, we really kind of look at that as being a real -- we're optimistic at this point in time as far as it being a really good long-term solution, if you will, or opportunity for us.

Suneet Kamath
Analyst at Jefferies Financial Group

Got it. And then my second question just on underwriting and remeasurement. So are you factoring in remeasurement gains into your plan for 2026 or are we sort of on-hold until we go through the unlocking assumption in the 3rd-quarter and then we kind of see what happens there?

Tom Kalmbach
Chief Financial Officer at Globe Life

Yeah. Our range is intended to encompass and encompass whether we continue to see favorable mortality trends consistent with where we saw them late in 2024 or they come back a little bit as well. So that's really what's intended in the range. And so I think there's a little bit of wait-and-see. We really -- there's no question we had a really good quarter in the 4th-quarter and we'd like to just see how that develops. And the development of 4th-quarter and then the results for first and second-quarter will inform any assumption update that we make in the 3rd-quarter of 2023.

Frank Svoboda
Co-Chief Executive Officer at Globe Life

And I think you said 2026, but I think you meant '25. I meant '25.

Tom Kalmbach
Chief Financial Officer at Globe Life

No, I mean, Tom's answers were for 2025. Yeah. I said 23 at the end, sorry.

Suneet Kamath
Analyst at Jefferies Financial Group

Yeah. Okay. Thanks.

Unidentified Speaker
at Globe Life

Yeah.

Operator

We will take our next question from Tom Gallagher, Evercore. Your line is open. Please go-ahead.

Tom Gallagher
Analyst at Evercore ISI

Hi, just first question on Bermuda. When you mentioned it might be a really good long-term solution or opportunity beginning in 2027. I assume that means that you see this more as a sustainable kind of ongoing free-cash flow benefit, not just like a one-time release. Is that a fair way to think about how you're -- how you're approaching it?

Tom Kalmbach
Chief Financial Officer at Globe Life

Yeah, Tom, that's exactly how I'm thinking about it is that it becomes part of an overall capital management strategy And strategy to return cash to shareholders.

Frank Svoboda
Co-Chief Executive Officer at Globe Life

And it really goes Tom to just think about capital requirements around the liability side of our balance sheet and the amount of managing that a little bit more efficiently through that jurisdiction

Tom Gallagher
Analyst at Evercore ISI

And would you be looking to fund it all yourself or are you contemplating third-party sidecar capital vehicles?

Tom Kalmbach
Chief Financial Officer at Globe Life

Yeah, not really considering third-party sidecar capital vehicles. We think it's really just really opportunity for us to do it ourselves that we don't think we need third-party capital to be able to make that an effective vehicle.

Tom Gallagher
Analyst at Evercore ISI

Got you. And then -- and just one question on -- final question on the health business. The -- how do we think about the timing of repricing? It sounds like what you've put in-place for repricing is somewhat below trend and that's why your margin guide is coming down. But how do I think about the timing of when -- when the periods of repricing occur? Is it most of it annual? Is it staggered throughout the year? And should we assume margins start low earlier part of '25 and gradually get better over the year? And what -- how do you think that also would play-out into '26?

Tom Kalmbach
Chief Financial Officer at Globe Life

Yeah. So the way that we go through rate filings and rate evaluation is we generally will make those determinations in the early 3rd-quarter and file those with the regulatory agencies. It's really an annual process rather than a continuous process throughout the year. And we did see quite a bit of the utilization come through in the earlier part of 2024 in the later part of '23. So a lot of the utilization was reflected in our rating -- our rate filings that we made with states.

It was really kind of the tail-end of '24 that we saw some incremental increases in utilization that didn't get factored in. So that would get factored in as well as the experience in early 2025 into our rate filings for -- that we make in 2025, which would then become effective in 2026. And those generally become effective right around the end-of-the first-quarter, beginning of the second-quarter is when those rates become effective?

Tom Gallagher
Analyst at Evercore ISI

Got you. And do you think based on the trend they're seeing, you'll be -- you would expect some level of improvement into '26 or is stable a better assumption for now?

Tom Kalmbach
Chief Financial Officer at Globe Life

Yeah. Yeah, it's hard to say because it really depends on what happens to utilization. But I think -- I think our plan would be to kind of catch-up with that into '26 and things would be more back to more normal. Now if utilization continue to increase above what our rate climbs were, we'd see a little bit of a drag there. And if they came back better, we'd see a little bit of a positive there as well. So that's kind of how we're thinking about it right now.

Frank Svoboda
Co-Chief Executive Officer at Globe Life

At least that is our hope is that it would -- we would catch-up if you will by 2026

Tom Gallagher
Analyst at Evercore ISI

Okay, thanks.

Operator

We will take our next question from, Raymond James, your line is open. Please go-ahead

Wilma Burdis
Analyst at Raymond James

Somebody covered my question thank

Operator

There are no further questions on the line, so I will now hand you back to your host for closing or additional remarks.

Stephen Mota
Senior Director, Investor Relations at Globe Life

All right. Thank you for joining us this morning. Those are our comments, and we will talk to you again next quarter.

Operator

Thank you for joining today's call. You may now disconnect

Corporate Executives
  • Stephen Mota
    Senior Director, Investor Relations
  • Frank Svoboda
    Co-Chief Executive Officer
  • Matt Darden
    Co-Chief Executive Officer
  • Tom Kalmbach
    Chief Financial Officer
  • Unidentified Speaker
Analysts

Alpha Street Logo

Transcript Sections